%0 Journal Article
%A Nieto Barbero, María Asunción
%A Sanchez-Pernaute, Olga
%A Vadillo, Cristina
%A Rodriguez-Nieto, Maria Jesus
%A Romero-Bueno, Fredeswinda
%A López-Muñiz, Belen
%A Cebrian, Laura
%A Rio-Ramirez, Maria Teresa
%A Laporta, Rosalia
%A Bonilla, Gema
%A Cobo, Tatiana
%A Leon, Leticia
%A Abasolo, Lydia
%A Nieto, Maria Asuncion
%A Vadillo, Cristina
%A Lores, Irene Martín
%A de Castro, Ana Bustos Garcia
%A Romero Bueno, Fredeswinda
%A Rodriguez Nieto, Maria Jesus
%A Pernaute, Olga Sanchez
%A Palacios, Carmelo
%A Carrera, Luis Gomez
%A Bonilla, Gema
%A Ortega, Gemma Mora
%A Cobo, Tatiana
%A López Muñiz, Belén
%A Cebrián, Laura
%A Godoy, Hilda
%A Laporta, Rosalia
%A Cubas, Irene Llorente
%A Valenzuela, Claudia
%A de Vicuña, Rosario Garcia
%A Jauregui, Ana
%A Rigual, Juan
%A Martos, Jesús Loarce
%A Hita, Jose Luis Morell
%T Functional respiratory impairment and related factors in patients with interstitial pneumonia with autoimmune features (IPAF): Multicenter study from NEREA registry
%D 2023
%@ 1465-993X
%U https://hdl.handle.net/20.500.14352/134799
%X Background The objective of the present study is to describe the characteristics of interstitial pneumonia withautoimmune features (IPAF) patients, to assess the incidence rate of functional respiratory impairment over time andto evaluate the influence of therapeutic alternatives on the prognosis of these patients.Methods A longitudinal observational multicenter study was performed (NEREA registry). It was carried out by amultidisciplinary team in seven Hospitals of Madrid. Patients were included from IPAF diagnosis. Main outcome: poorprognosis as functional respiratory impairment (relative decline in FVC % defined as≥5% every 6 months). Covariates:therapy, sociodemographic, clinical, radiological patterns, laboratory and functional tests. Statistics: Survival tech‑niques were used to estimate IR per 100 patients-semester with their 95% confidence interval [CI]. The influence ofcovariates in prognosis were analyzed through cox multivariate regression models (hazard ratio (HR) and [CI]).Results 79 IPAF were included, with a mean and a maximum follow-up of 3.17 and 12 years respectively. Alongthe study, 77.2% received treatment (52 glucocorticoids, 25 mycophenolate, 21 azathioprine, 15 rituximab and 11antifibrotics). IR was 23.9 [19.9–28.8], and 50% of IPAF developed functional respiratory impairment after 16 monthsfrom its diagnosis. Multivariate analysis: usual interstitial pneumonia (UIP) had poorer prognosis compared to nonspecific interstitial pneumonia (NSIP) (p=0.001). In NSIP, positive ANA, increased the risk of poor prognosis. In UIP,glucocorticoids (HR: 0.53 [0.34–0.83]), age (HR: 1.04 [1.01–1.07]), and Ro-antibodies (HR: 0.36 [0.19–0.65]) influencedthe prognosis.Conclusions IPAF have functional impairment during the first years of disease. Factors predicting deterioration differ
%~